title: [Progress in pharmacotherapy of pulmonary arterial hypertension in children].
abstract: This paper provides an overview of the current state of pharmacotherapy in children with pulmonary arterial hypertension (PAH) and a brief introduction to the potentially novel pharmacologic targets for PAH. Currently, 3 classes of drugs including prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase-5 inhibitors are approved for the treatment of PAH in children, which has led to improved hemodynamics, increased exercise capacity and prolonged survival. Despite these improvements, there is still a need to carry out well-designed, randomized, controlled studies with larger samples. In addition, novel drugs targeting other molecular pathways should be developed.
authors.affiliation: Department of Pediatrics, First People's Hospital of Hangzhou, Hangzhou 310006, China. yyp757605@163.com
authors.forename: Yan-Ping
authors.initials: YP
authors.lastname: Yu
authors.forename: Xian-Mei
authors.initials: XM
authors.lastname: Huang
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077300:Bosentan; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002648:Child; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D065627:Familial Primary Pulmonary Hypertension; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*; D016285:Iloprost / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D013449:Sulfonamides; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D011464:Epoprostenol; D016285:Iloprost; C049347:fasudil; D000077300:Bosentan; C427248:treprostinil